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1. Introduction
Hypothyroidism, a common endocrine and metabolic
disorder, is a clinical syndrome caused by the insufﬁciency
in the synthesis, secretion, or biological efﬁcacy of the
thyroid hormone [1]. Hypothyroidism accelerates athero-
sclerosis and increases the incidence of atherosclerotic
ischemic stroke [2]. Thrombolytic treatment with intrave-
nous recombinant tissue plasminogen activator (rtPA) is an
effective treatment for acute ischemic stroke [3]. However,
its effectiveness and risks in patients with hypothyroidism
have not been reported. We report a patient with
acute ischemic stroke and hypothyroidism who died of
hemorrhagic transformation after receiving intravenous
rtPA thrombolysis treatment.
2. Case report
A 53-year-old right-handed male patient was hospitalized
1.5 h after experiencing sudden slurred speech and muscle
weakness in the right extremities. He had a 5-year history of
hypertension and 3-year history of hypothyroidism, and had
been taking 50 mg qd of levothyroxine sodium tablets. On
admission, the patient was conscious, and showed dysarthria,
right central facial paralysis, 1/5 myodynamia in the right
upper extremity, 0/5myodynamia in the right lower extremity,
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Thrombolytic treatment with intravenous recombinant tissue plasminogen activator (rtPA)
is an effective treatment for acute ischemic stroke. However, its effectiveness and risks in
patients with hypothyroidism have not been reported. Here, we report the case of hemor-
rhagic transformation after intravenous rtPA thrombolysis treatment in a patient with acute
ischemic stroke and hypothyroidism. An apparent edema formed around the hematoma
and progressively worsened. He also developed lung infection, electrolyte imbalance, and
abnormal liver and kidney functions, and eventually diedwithin 1month of symptomonset.
Thus, our observations suggest that caution should be exercised for the administration of
intravenous rtPA thrombolysis to patients with hypothyroidism.
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5/5 myodynamia in the left limbs, hypalgesia in the right side
of the body, and blood pressure of 170/90 mmHg. Cranial
computed tomography (CT) taken 1.5 h after onset did not
show any abnormalities (Fig. 1). Routine blood test, coagula-
tion function, and liver and kidney functions were all normal.
A random blood glucose level of 8 mmol/L was obtained, and
the patient's National Institute of Health Stroke Scale (NIHSS)
score was 12. Thus, the patient was treated with 70 mg
intravenous rtPA thrombolysis 3 h after the onset based on a
dosage of 0.6 mg/kg body weight (patient's body weight
115 kg), in addition to intravenous urapidil antihypertensive
therapy. Upon completion of the rtPA thrombolysis treatment,
the patient regained consciousness, but showed dysarthria,
right central facial paralysis, 2/5 myodynamia in the right
upper extremity, 1/5myodynamia in the right lower extremity,
and 5/5 myodynamia in the left limbs. One hour after
rtPA thrombolysis treatment, the patient experienced head-
ache, vomiting, and drowsiness. Cranial CT reexamination
revealed hemorrhage in the right temporal lobe extending to
the outer right side, a parenchymal hematoma approximate
3.5 cm  2 cm  4 cm in size, and a spotted hemorrhage in the
left basal ganglia (Fig. 2). Cranial CT reexamination 24 h later
showed no increase in bleeding, an apparent compression of
the right ventricles, a slight left shift of the midline, and a left
basal ganglia infarction with hemorrhage (Fig. 3). The patient
was lethargic, opened his eyes on stimulation, presented
occasional spontaneous movement of the left limbs, and did
not respond to stimulation on the right limbs. Thyroid
function test results were all signiﬁcantly below normal levels
as follows: thyroxine (T4), 26.4 nmol/L (66–181 nmol/L); free
[(Fig._1)TD$FIG]
Fig. 1 – Cranial computed tomography before recombinant
tissue plasminogen activator thrombolysis shows no
hemorrhage.
[(Fig._3)TD$FIG]
Fig. 3 – Cranial CT 24 h after rtPA thrombolysis shows
hemorrhage in the right temporal lobe surrounded by
edema, compressed right ventricle, infarction, and spotted
hemorrhage in the left basal ganglia.
[(Fig._2)TD$FIG]
Fig. 2 – Cranial CT 1 h after rtPA thrombolysis shows
hemorrhage in the right temporal lobe and spotted
hemorrhage in the left basal ganglia.
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thyroxine (FT4) 3.47 pmol/L (12–22 pmol/L); triiodothyronine
(T3) 0.42 nmol/L (1.3–3.1 nmol/L); and free triiodothyronine
(FT3) 1.54 pmol/L (3.1–6.8 pmol/L). Thyroid-stimulating hor-
mone (TSH) 65.7 mIU/L (0.27–4.2 mIU/L) and anti-thyroid
peroxidase antibody (ATPO) 252.1 IU/mL (0–34 IU/mL) levels
were signiﬁcantly above normal levels. Considering primary
hypothyroidism of the patient, oral administration of
levothyroxine sodium tablet was administered in gradually
increased dosage. As the patient showed apparent intracranial
edema, a combination ofmannitol, albumin, and bloodplasma
drip was given to reduce the symptom. Cranial CT reexami-
nation 3 days later showed no increase in cerebral bleeding,
apparent edema, and compression of the right ventricle
(Fig. 4). Cranial CT reexamination 14 days later showed that
the blood was almost absorbed, whereas the apparent edema,
compression of the right ventricle, and left shift of themidline
persisted (Fig. 5). Thyroid function re-examination showed a
gradual increase in T4 and FT4 levels to almost normal levels, a
decrease in TSH level, and no noticeable change in T3 and FT3
levels. The patient constantly appeared lethargic, and gradu-
ally developed a lung infection, electrolyte imbalance, and
abnormal liver and kidney function. The patient voluntarily
discharged after 22 days of hospitalization. On discharge, the
patient lost consciousness, occasionally opened his eyes, and
had an automatic respiratory rhythm of 17 breaths/min and a
heart rate of 100 beats/min. He died 1 day later.
3. Discussion
The patient in our case had no contraindication for
rtPA thrombolysis, and was treated with intravenous rtPA
thrombolysis 3 h after acute ischemic stroke onset. Blood tests
performed before rtPA thrombolysis were unremarkable.
However, after rtPA thrombolysis, hemorrhagic transforma-
tion occurred. Incidence of hemorrhagic transformation after
rtPA thrombolysis administered within 3 h of ischemic stroke
is about 6% [4], occurring mainly due to coagulation disorder
and damage of the blood–brain barrier caused by rtPA. Factors
associated with hemorrhagic transformation include ad-
vanced age, serious stroke at baseline, large area of baseline
infarction, hyperglycemia, hypertension, a history of anti-
platelet drug use, atrial ﬁbrillation, congestive heart failure,
and impaired renal function [4]. The patient had a normal
blood glucose level, and his controlled pre-thrombolysis blood
pressure waswithin the recommended range. He had no other
risk factors and the dosage of rtPA (0.6 mg/kg) was low;
however, hemorrhage still occurred. Thus, further investiga-
tion was needed to explore the cause of hemorrhagic
transformation. Vascular lesions form and progressively
worsen in the early stage of cerebral focal ischemia [5]. This
can damage the blood–brain barrier and increase the risk of
hemorrhagic transformation. Collateral circulation could
reduce the damage to the ischemic vessels, and thus,
perfusion status has been closely related to hemorrhagic
transformation after revascularization [6,7]. Research has
shown that patients with poor collateral circulation have a
higher risk of hemorrhage after recanalization of blood vessels
[8]. It is known that hypothyroidism increases the incidence of
risk factors associated with atherosclerosis, such as hyperten-
sion, hyperlipidemia, endothelial dysfunction, hyperhomo-
cysteinemia, and elevated hypersensitive C-reactive protein
level, which can further accelerate the progress of atheroscle-
[(Fig._4)TD$FIG]
Fig. 4 – Cranial CT 3 days after rtPA thrombolysis shows no
increase in bleeding but apparent edema, compressed right
ventricle, and left shifted midline.
[(Fig._5)TD$FIG]
Fig. 5 – Cranial CT 14 days after rtPA thrombolysis shows
that hematoma is absorbed. Apparent edema, compressed
right ventricle, and left shifted midline are still visible.
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rosis [2,9]. It is speculated that hypothyroidism in our patient
caused extensive atherosclerosis, poor collateral circulation,
poor perfusion status, and elevated risk of hemorrhage after
recanalization of blood vessels. The patient exhibited left basal
ganglia infarction and the offending vessels were the
perforating branches of the middle cerebral artery. Recanali-
zation of vessels occurred after rtPA thrombolysis and
hemorrhage occurred at the left basal ganglia. Since athero-
sclerosis is a risk factor for intracranial hemorrhage, the
hemorrhage at the right temporal lobe of the patient may be
related to signiﬁcant atherosclerosis, damaged blood vessels
after infusion of rtPA, and damage to the blood–brain barrier.
Because the patient had none of the risk factors that could
increase hemorrhage, and the rtPA dose was low, it was
necessary to consider extensive atherosclerosis caused by
hypothyroidism as a cause for hemorrhage.
The actual hemorrhage was about 14 mL after hemorrhagic
transformation, but the edema was apparent. Application of
mannitol, albumin, and blood plasma drips did not effectively
alleviate the edema. Related studies show that hemorrhage
after rtPA thrombolysis may cause milder edema compared
with that in spontaneous intracerebral hemorrhage [10]. The
prognosis of an intracerebral hemorrhage is directly related to
the amount of hemorrhage, and patients who have less than
25 mL of hemorrhage tend to have a better prognosis [11]. This
patient had 14 mL of hemorrhage, but had persistent edema,
and eventually died. In the case of hypothyroidism, glycos-
aminoglycan accumulates under vascular endothelia, while
the capillary walls become less efﬁcient as a barrier, causing
plasma protein and serum to leak into the interstitial spaces,
and result in edema. Themechanismof edema formation after
intracerebral hemorrhage is vasogenic. Because of the in-
creased microvascular permeability, protein-containing ﬂuid
enters the interstitial spaces and leads to edema. In our
patient, hypothyroidism increased the permeability of the
capillary walls and consequent damage to the blood–brain
barrier. This increased the amount of protein-containing ﬂuid
entering the interstitial spaces, thus causing the vasogenic
edema to deteriorate. Consequently, an apparent edema with
minor hemorrhage developed. Dehydrant did not have a
signiﬁcant effect and the edema was still signiﬁcant after the
hematomas were absorbed. The patient eventually died.
Hypothyroidism is a risk factor for atherosclerosis, and
accelerates the progress of atherosclerosis and increases the
risk of atherosclerotic ischemic stroke. Incidence of ischemic
stroke in patients with hypothyroidism is higher than that in
the general population, although patients with hypothyroid-
ism have better prognoses after ischemic stroke. Research
reveals that after a transient ischemic attack, hypothyroidism
does not protect the hippocampal neurons but delays their
death [12]. Due to the pre-tolerance of hypoxia and reduced
sensitivity to physical stress in patients with subclinical
hypothyroidism, the prognosis of these patients after infarc-
tion are better than that in patients without hypothyroidism
[13,14]. Similarly, the prognosis may also be better in patients
with hypothyroidism. However, these patients have a higher
risk of hemorrhage after rtPA thrombolysis and develop
signiﬁcant edema, which affects prognosis. These indicate
that hypothyroidism should be considered as a relative
contraindication to intravenous rtPA thrombolysis therapy,
or that the choice of rtPA thrombolysis for the treatment of
patients with both hypothyroidism and acute ischemic stroke
should be made with great caution.
The non-thyroidal illness syndrome (NTIS; or 'euthyroid
sick syndrome', or low-T3 syndrome) describes abnormalities
in thyroid function tests in the absence of obvious thyroid
disease [15]. Themost common abnormality is a decrease in T3
levels; in the presence ofmore severe illness, a fall in the levels
of T4 occurs while the TSH levels do not elevate. Low T3 is a
strong predictor of outcome in acute stroke patients [16]. In
this case, TSH level was signiﬁcantly above normal level and
the patient presented hypothyroidism, it was different from
this syndrome. However, the lowT3 level is also related to poor
prognosis in this case.
In this case, the patient had both hypothyroidism and
acute ischemic stroke, and hemorrhagic transformation and
severe edema occurred after low-dose rtPA thrombolysis.
Because of the critical condition of the patient, cerebral
magnetic resonance imaging and vascular examinations
were not taken. Based on this case, it is suggested that the
rtPA thrombolysis treatment should be considered with great
care for patients with acute ischemic stroke and hypothy-
roidism. However, this was based on the data from one
patient, and accumulation of cases and related basic research
studies are needed to be conclusive and provide better
treatment options to patientswith hypothyroidismand acute
ischemic stroke.
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